Adds trial details in paragraph 2, disease background in paragraph 3 and share movement in paragraph 4
Dec 17 (Reuters) - Sanofi SASY.PA and Teva Pharmaceuticals TEVA.TA said on Tuesday that their drug, duvakitug, met the main goals in a mid-stage trial when tested in patients with inflammatory bowel disease $(IBD)$.
The drug met the main goals of disease remission and effectiveness for the treatment of ulcerative colitis and Crohn's disease, respectively.
These are the two most common forms of IBD, which affects between 2.4 million and 3.1 million people in the U.S.
U.S.-listed shares of Teva rose nearly 14%, while U.S.-listed shares of Sanofi climbed 4% premarket.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
((Christy.Santhosh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。